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Abstract
Although diabetes mellitus is predominantly a metabolic disorder, recent data suggest that it is as
much a vascular disorder. Cardiovascular complications are the leading cause of death and disability
in patients with diabetes mellitus. A number of recent reports have emphasized that many patients
already have atherosclerosis in progression by the time they are diagnosed with clinical evidence
of diabetes mellitus. The increased risk of atherosclerosis and cardiovascular complications in
diabetic patients is related to the frequently associated dyslipidemia, hypertension, hyperglycemia,
hyperinsulinemia, and endothelial dysfunction. The evolving knowledge regarding the variety of
metabolic, hormonal, and hemodynamic abnormalities in patients with diabetes mellitus has led to
efforts designed for early identification of individuals at risk of subsequent disease. It has been
suggested that insulin resistance, the key abnormality in type II diabetes, often precedes clinical
features of diabetes by 5–6 years. Careful attention to the criteria described for the cardiovascular
dysmetabolic syndrome should help identify those at risk at an early stage. The application of
nonpharmacologic as well as newer emerging pharmacologic therapies can have beneficial effects
in individuals with cardiovascular dysmetabolic syndrome and/or diabetes mellitus by improving
insulin sensitivity and related abnormalities. Early identification and implementation of appropriate
therapeutic strategies would be necessary to contain the emerging new epidemic of cardiovascular
disease related to diabetes.
Although the importance of diabetes mellitus (DM) as a
major risk factor for macrovascular and microvascular dis-
ease is well recognized, the recent increase in the preva-
lence of DM, especially in younger individuals, has raised
alarm. It is probable that the increased incidence of DM
will slow the age-adjusted decline in coronary heart dis-
ease (CHD) and will even raise the possibility of a signif-
icant increase in the risk of cardiovascular (CV) disease
during the next several decades. Recent data from the
Center for Disease Control showed that, although there
was an increase in the prevalence of DM across all ethnic
groups and all ages, the most striking increase (by 70%)
was observed in people aged between 30 and 39 years.
These data suggest that there is not only an increase in the
prevalence of DM, but that the disease is occurring at
younger ages and that such trends, if uninterrupted, can
potentially lead to a new epidemic of CV disease during
this millennium.
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CV complications are the leading cause of death and disa-
bility in patients with type II DM [1]. The magnitude of
CV complications in DM is best illustrated by a recent re-
port demonstrating that the risk of myocardial infarction
in diabetic patients with no prior myocardial infarction
was as high as that in nondiabetic patients with a history
of prior myocardial infarction [2]. Although it has been
known for years that DM is a major coronary risk factor,
the precise mechanism for the increased risk of CHD in
patients with DM has not been well defined [3–6].
Several studies have evaluated the role of potential factors
that could increase the risk of atherosclerosis in associa-
tion with DM [7–10]. The results of these studies demon-
strate that there are a number of pathways by which DM
increases the risk of CHD. Most diabetic patients frequent-
ly have one or more of the well-established risk factors, in-
cluding hypertension, dyslipidemia, and obesity [7].
Although these are well-established, independent risk fac-
tors in nondiabetic patients, they can only account for ap-
proximately one-half of the excess CHD risk associated
with DM [6]. The additional risk of CHD must therefore
be partly accounted for by the predominant metabolic ab-
normalities in DM, which are hyperglycemia and hyperin-
sulinemia due to insulin resistance [7,8].
A number of recent studies have documented a relation-
ship between the risk of CHD events and hyperglycemia,
increased levels of glycated hemoglobin (HgA1C), and hy-
perinsulinemia [2–10]. Whether these metabolic abnor-
malities play a direct role in the pathogenesis of
atherosclerosis or increase the risk of CHD due to other as-
sociated risk factors is currently being investigated.
Based on the available information, it appears that hyper-
insulinemia secondary to insulin resistance is an impor-
tant and independent risk factor for CHD [5–12]. The
strongest evidence to support the association between hy-
perinsulinemia and CHD events comes from the prospec-
tive study of men from Quebec, which demonstrated a
fourfold to fivefold increase in the risk of CHD in individ-
uals with the highest levels of fasting plasma insulin [8].
The precise pathogenetic mechanism by which insulin in-
creases the risk of atherosclerosis and CHD has not been
established [1]. However, several possibilities exist. Insu-
lin might contribute to the risk of hypertension by stimu-
lating sympatho-adrenal axes through modulation of
cation transport and vascular remodeling by stimulating
hypertrophy of vascular smooth cells [9]. Insulin not only
enhances the effects of platelet-derived growth factor, but
also directly stimulates vascular smooth cell hypertrophy
[11]. Hyperinsulinemia can also produce dyslipidemia
(e.g. increase triglyceride and decrease high-density lipo-
protein cholesterol by increasing catecholamine levels
and by increased synthesis of very low-density lipoprotein
[7,8,11,12]. In addition, the increased levels of glucose
and insulin promote secretion of plasminogen activator
inhibitor-1, which increases the risk of thrombosis by pro-
ducing a prothrombotic state [11]. Diabetic patients also
have increased levels of serum fibrinogen and von Wille-
brand factor, which further enhance thrombosis.
Clinical relevance of cardiovascular dysmetabol-
ic syndrome
It is now well recognized that endothelial dysfunction and
injury are key initial steps in the process of atherosclerosis.
Many of the factors associated with insulin resistance can
also lead to endothelial dysfunction directly or indirectly.
Although in the normal physiologic state insulin stimu-
lates production of nitric oxide by endothelial cells, recent
studies have shown that in a hyperinsulinemic state en-
dothelial response to insulin is impaired [11]. The pres-
ence of endothelial dysfunction has also been
demonstrated in association with hyperglycemia and in
patients with type II DM [11]. In addition, the increased
oxidative stress in association with diabetes can further
impair endothelial function. It is thus clear that diabetes
and the associated insulin resistance have damaging ef-
fects on the endothelium that, together with the cluster of
associated abnormalities, increase the risk of atherosclero-
sis and CHD [1].
It has been suggested that as many as 50% of newly diag-
nosed patients with type II DM might already have evi-
dence of CHD [3–6]. It is therefore conceivable that the
insulin resistance that often precedes the development of
clinical signs and symptoms of type II DM is responsible
for the increased risk of CHD [7–11]. Several studies have
demonstrated that insulin resistance and hyperinsuline-
mia often coexist with other metabolic abnormalities that
increase the risk of CHD (Table 1) [7–11]. Although insu-
lin resistance syndrome has been recognized for some
time as syndrome X or Reaven's syndrome, this was re-
cently redefined as cardiovascular dysmetabolic syn-
drome (CDS) [12,13]. This newly coined term appears to
be more logical because it includes all of the important el-
ements of the syndrome and it highlights the involvement
of the CV system in this dysmetabolic state.
CDS has four critical elements: dyslipidemia, insulin re-
sistance, obesity, and high blood pressure (easily remem-
bered by the mnemonic DROP) (Table 2) [13]. A
diagnosis of CDS requires the presence of at least two of
the first three components: dyslipidemia, insulin resist-
ance, and obesity [13]. All components of CDS are risk
factors for macrovascular disease (coronary disease, carot-
id disease, cerebral disease, and peripheral vascular dis-
ease). The presence of more than one component confers
additive risk, although some components (e.g. diabetes orCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/2
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insulin resistance) confer more risk than others [13]. It is
important to note that, whereas the presence of DM dou-
bles the risk of macrovascular disease in men, this risk is
increased by fourfold to fivefold in women. Women with
diabetes thus lose the gender protection and are at equally
high risk of CHD as men of the same age and risk profile
[13].
When and how to screen for CDS
Although it is difficult to define insulin resistance (the
critical element of CDS) in the clinical setting, it has been
suggested that fasting plasma glucose ≥  110 mg/dl identi-
fies most individuals with an insulin-resistant state [13–
15]. The other elements of CDS, such as obesity and hy-
pertension, require only good physical examination and
measurement of weight, waist circumference, and blood
pressure. Those with an increased waist-hip ratio (> 0.9)
and/or truncal obesity can be suspected to have an insu-
lin-resistant state. A simple, fasting lipid panel would
identify those patients with most common and critical dy-
slipidemia.
The new criteria of the American Diabetes Association
have also lowered the cut-off point that defines DM to
fasting glucose ≥  126 mg/dl, in recognition of the microv-
ascular disease that is often seen with glucose values
above that level [15]. Fasting glucose ≥  126 mg/dl corre-
sponds to a postprandial glucose ≥  200 mg/dl, 2 hours af-
ter a 75 g glucose load, and either one of these values
denotes the presence of DM [14,15]. It has also been rec-
ommended that any casual nonfasting blood glucose ≥
200 mg/dl indicates the presence of DM [14,15]. It is im-
portant to note that, although good control of glucose lev-
els decreases the risk of microvascular disease, patients
with well-controlled glucose continue to be at increased
risk of macrovascular disease due to persistence of insulin
resistance, hyperinsulinemia, and associated metabolic
and hemodynamic abnormalities [13,14].
Although routine screening for DM should be carried out
at 3-year intervals starting at 45 years of age, earlier and
more frequent screening is recommended for individuals
who have one or more elements of CDS, for those who
have a family history of DM, and for members of high-risk
ethnic groups (e.g. Hispanics, native Americans, or mi-
grant Southeast Asians) [15].
Therapeutic strategy in CDS and DM
There are numerous nonpharmacologic and pharmaco-
logic interventions that can have beneficial effects in indi-
viduals with CDS and/or DM. Nonpharmacologic
measures should always be the initial therapeutic inter-
vention in individuals with CDS [13]. Although weight re-
duction by as little as 10% of body weight can improve
insulin sensitivity, it is generally desirable to reduce
weight to the ideal level, achieving body mass index < 25
kg/m2[13]. Regular aerobic physical exercise can substan-
tially improve insulin sensitivity and, in many cases, im-
prove many of the abnormalities seen in CDS. It has been
suggested that even low levels of exercise, such as brisk
Table 1: Frequently observed metabolic, hemostatic, and other 
abnormalities in cardiovascular dysmetabolic syndrome
↑ Insulin
↑ Levels of insulin growth factor
↑ Intra-abdominal fat
↑ Fatty acids
↑ Triglycerides
↓ High-density lipoprotein cholesterol
↑ Small dense low-density-lipoprotein cholesterol
↑ Apolipoprotein B
↑ Tissue angiotensin II levels
↑ Serum fibrinogen
↑ Plasminogen activator inhibitor-1
↑ Oxidative stress
↓ Synthesis of endothelial derived relaxation factor (nitric oxide)
↑ , increased; ↓ , decreased
Table 2: Cardiovascular dysmetabolic syndrome
Dyslipidemia 
(D)
Fasting triglycerides > 140 mg/dl, or 
High-density lipoprotein cholesterol < 40 mg/dl, or 
Low-density lipoprotein particle size < 260 Å
Insulin 
resistance (R)
Fasting plasma glucose ≥  110 mg/dl, or 
Type 2 diabetes mellitus
Obesity (O) Body mass index > 25 kg/m2, or 
Waist-hip ratio > 0.85, or 
Waist > 100 cm
High blood 
pressure (P)
Systolic blood pressure ≥  140 mmHg, or 
Diastolic blood pressure ≥  90 mm Hg
Table 3: Effects of thiazolidinedione insulin sensitizers
↓ Insulin resistance
↓ Hyperinsulinemia
↓ Fasting blood sugar in type 2 diabetes mellitus
↓ Free fatty acids
↓ Triglycerides
↑ High-density lipoprotein cholesterol
↓ Plasminogen activator inhibitor-1 activity
↑ Vascular compliance
↓ Blood pressure/vascular resistance
↓ Macrophage inflammatory activity
Direct vascular effects
↑ , increased; ↓ , decreasedCurrent Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/2
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walking for 30–45 min three to five times a week, are use-
ful in improving insulin sensitivity.
There are several pharmacologic modalities that can be
used for patients with DM and CDS. In patients with DM,
although exogenous insulin supplements endogenous
production by the pancreas, it does not improve insulin
resistance and it often causes hunger and additional
weight gain. Sulfonylureas work by stimulating produc-
tion of insulin and would have the same metabolic draw-
backs as exogenous insulin. Alpha-glucosidase inhibitors,
such as acarbose, delay carbohydrate absorption and de-
crease the stimulation for endogenous insulin secretion
[16]. Their use is limited due to gastrointestinal side ef-
fects.
Biguanides, such as metformin, primarily decrease hepatic
glucose production and, to a limited extent, reduce insu-
lin resistance [17]. Although rare, metformin can cause fa-
tal lactic acidosis, particularly in patients with renal or
hepatic dysfunction. However, it can improve insulin sen-
sitivity and can help reduce weight in some individuals
[18].
The thiazolidinediones, such as pioglitazone or rosiglita-
zone, reduce insulin resistance in muscle [19] and, to a
lesser extent, reduce hepatic glucose production [20].
These actions lower both plasma glucose and insulin. This
class of agents also has other beneficial effects. Thiazolid-
inediones inhibit cell growth and migration in the setting
of vascular injury [21]. The thiazolidinediones can de-
crease blood pressure by reducing peripheral vascular re-
sistance due to improved endothelial function [22]. Some
of these agents can increase high-density lipoprotein cho-
lesterol and decrease triglyceride levels [22]. Low-density
lipoprotein cholesterol might increase without an in-
crease in apolipoprotein B in some cases, indicating an in-
crease in low-density lipoprotein particle size without an
increase in number of particles, which may have an anti-
atherogenic effect [23,24]. A number of ongoing studies
are now evaluating the CV benefits of treatment with thi-
azolidinediones (pioglitazone and rosiglitazone) in pa-
tients with type II DM. Although improvement in insulin
sensitivity with these agents might be beneficial in the
short term, we need to evaluate their long-term safety and
efficacy, especially in light of the serious adverse experi-
ence observed with troglitazone.
In summary, treatment of type II DM should emphasize
improvement in insulin sensitivity, a decrease in hepatic
glucose production, and a decrease in stimulation of en-
dogenous insulin production, rather than increased en-
dogenous insulin production or exogenous
administration of insulin. Future drug development in
this area should focus on drugs that can improve several
of these abnormalities. It is only through development of
such therapy, as well as public health measures directed to
reducing obesity in the population at large, that we will be
able to control this emerging epidemic of the 21st century.
Conclusion
Recent data show that the prevalence of type II diabetes is
rapidly increasing in the world. People are also develop-
ing DM at a younger age, and this trend is likely to contin-
ue with increased prevalence of obesity in the adolescent
and youth years. DM has clearly become a major public
health issue and it is likely to result in a new epidemic of
premature coronary artery disease in the new millennium.
It is therefore critical to identify those individuals at future
risk of developing DM. Early identification by regular
evaluation for CDS in susceptible individuals should help
to identify the high-risk individuals who will benefit from
aggressive nonpharmacologic as well as pharmacologic
measures (when necessary) directed toward decreasing
their risk for developing DM and CV disease.
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